To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

January 25, 2019

Today's Rundown

Featured Story

Vertex strikes deal with Merck KGaA to grow CRISPR/Cas9 toolkit

Vertex has regained limited rights to two DNA-dependent protein kinase inhibitors from Merck KGaA. Merck licensed the drugs and other assets for $230 million upfront two years ago but has now granted Vertex the right to use them in certain gene-editing applications. 

Top Stories

U.K. calls for globally organized incentives for antibiotic R&D

The U.K. wants the international community to come up with a coordinated system for incentivizing the development of antimicrobials. Government officials floated the idea in a report setting out how the U.K. plans to tackle the threat posed by drug-resistant bacteria over the next five years.

Midatech ‘urgently’ needs investor as cash reserves dwindle

Midatech Pharma is running out of money and says it needs an investor to come on board quickly if it is to rescue its lead drug for carcinoid cancer and acromegaly.

U.K. government to invest £100M in artificial intelligence-focused Ph.D.s

As the hard date for Brexit approaches, the U.K. government announced it would invest £100 million ($130 million) to attract 1,000 new Ph.D. placements at universities across the country focused on artificial intelligence development, including for the life sciences industry.

EuroBiotech Report—Novartis, Immunocore-Scancell, Wren A round, Novo and BioNTech

In this week's EuroBiotech Report, Novartis inks big data tie up, Immunocure loses long-term staffer and Wran raises £18 million. 

FiercePharmaAsia—Sun's new headache; Takeda asset sale?; Chinese CAR-T player financing

Sun Pharma makes structural changes as a new whistleblower allegation cuts investor confidence; Takeda reportedly looks to sell $3 billion worth of products in emerging markets; Beijing biotech Immunochina raises $20 million to fund trials of its lead CAR-T therapy; and more.

Chutes & Ladders—GSK chairman bows out as company prepares for split-up

GSK Chairman Philip Hampton has bowed out as the company prepares to split up; CEO Katrine Bosley has signed off from CRISPR pioneer Editas; Roche has dispatched strategy executive Alexander Hardy to take the helm at Genentech; and Vertex fires COO Ian Smith for a code-of-conduct violation. Those moves plus more hirings, firings and retirings throughout the industry.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Better Market Intelligence With Smart Search

It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence.

[POCKET GUIDE] 3 Steps To Supercharge Your Literature Search

Go from Search to Full-Text Scientific Papers in a Single Click!

[Whitepaper] Achieving launch excellence in the challenging healthcare markets of today

This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets.

[Whitepaper] Accelerate Time To Market Working With Industry Specialist MSP

With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market.

[Whitepaper] Liquid Biopsy Investor Toolkit

With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners.

[Survey] Veeva 2019 Unified Clinical Operations Survey

Share your thoughts on the life sciences industry's progress in improving study execution.

[Whitepaper] The 3DP Revolution: Planning Effective Brand Extension for In-Market Drugs

Get ahead of looming challenges in the market that include both generic products and new branded drugs.

[Infographic] Clinical Development Trends And The Impact On Clinical Trial Technology

New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM).

[Webinar] Building the Business Case for Transformational RIM

Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events